AMA expands advocacy efforts supporting drug price transparency

| 3 Min Read

HONOLULU — Given that pharmaceutical companies, pharmacy benefit managers and health insurance companies have overlapping roles that affect prescription drug prices, physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy to expand the scope of its federal and state advocacy efforts to increase transparency of drug pricing.

“As spikes in prescription drug prices occur without justification, the American Medical Association believes we need more transparency to protect patients from drug price gouging and manipulation,” said AMA President-elect Barbara L. McAneny, M.D. “Greater transparency among pharmaceutical manufacturers, pharmacy benefit managers and health plans will shed light on the rationale for drug price increases and why patients pay what they do for their medications.”

Full press release available when you sign in

Sign in to the AMA website to get the full version of this press release. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Man power walking or jogging, with dumbbells

New changes expand diabetes-prevention for more Medicare patients

| 3 Min Read
Three healthcare workers in discussion

AMA Joy in Medicine points the way to better care

| 5 Min Read
Doctors hold up magnifying glasses over a giant pancreas

Beyond watch and wait: Taking aim at pancreatic cysts

| 7 Min Read
Philip Kuriakose, MD, featured on "Health vs. Hype" AMA podcast

5 things patients should know about microplastics

| 8 Min Read